Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharmather Hldgs Ltd (PHRM.CN)

Pharmather Hldgs Ltd (PHRM.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 8,192
  • Shares Outstanding, K 91,019
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,526 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 4.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.44
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 10/30/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0850 unch
on 01/20/26
0.1100 -22.73%
on 12/30/25
-0.0200 (-19.05%)
since 12/19/25
3-Month
0.0850 unch
on 01/20/26
0.1600 -46.88%
on 11/18/25
-0.0500 (-37.04%)
since 10/20/25
52-Week
0.0850 unch
on 01/20/26
0.7700 -88.96%
on 08/11/25
-0.1250 (-59.52%)
since 01/17/25

Most Recent Stories

More News
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
PharmaTher CEO Publishes Letter to Shareholders

Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
Upcoming Meeting Dates - November 3, 2025

Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - The following is a list of Upcoming Meeting Dates for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service...

KEC.TO : 24.73 (+0.12%)
SUP.VN : 2.590 (+3.60%)
FMT.VN : 6.580 (+2.81%)
BARU.VN : 0.060 (unch)
SPN.VN : 0.040 (-11.11%)
ESBL.VN : 0.150 (unch)
GRDM.VN : 0.155 (-6.06%)
VGD.VN : 0.175 (+2.94%)
ESAU.CN : 0.7000 (-4.11%)
NTE.VN : 0.100 (unch)
PRR.CN : 0.0900 (+12.50%)
BY.CN : 0.0700 (+16.67%)
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

Company preparing FDA meeting package to align on a single, well-controlled Phase 3 study under 505(b)(2); Pharma partner discussions ongoingToronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings

Expanding ketamine indications, fortifying IP, enabling earlier partnerships, and accelerating FDA pathways - underpinned by PharmaTher's Digital Health AI division, leveraging the Company's FDA-approved...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease

Phase 3 program targeting a potential US$2.2B U.S. market opportunity505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and timeFDA-reviewed CMC package validated through prior...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)
PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy

TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical...

PHRM.CN : 0.0850 (-5.56%)
PHRRF : 0.0646 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch and others.

See More

Key Turning Points

3rd Resistance Point 0.0933
2nd Resistance Point 0.0917
1st Resistance Point 0.0883
Last Price 0.0850
1st Support Level 0.0833
2nd Support Level 0.0817
3rd Support Level 0.0783

See More

52-Week High 0.7700
Fibonacci 61.8% 0.5083
Fibonacci 50% 0.4275
Fibonacci 38.2% 0.3467
Last Price 0.0850
52-Week Low 0.0850

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar